NCT06802718View on ClinicalTrials.gov

Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia

PHASE3RecruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Interferon

Polyethylene glycol interferon alpha-2b injection 135 μg/week was subcutaneously given for 6 months.

Trial Locations (1)

100044

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER